How T Cells Make Sure They Have Quiet Time
All cells, like all people, need “quiet” time to function properly, and this is particularly true of T cells, one of the immune system’s main weapons. They must be ready for activation at all times, and primed to divide more rapidly than almost any cell in the body.
Yale Scientists Breach Brain Barriers to Attack Tumors
The brain is a sort of fortress, equipped with barriers designed to keep out dangerous pathogens. But protection comes at a cost: These barriers interfere with the immune system when faced with dire threats such glioblastoma, a deadly brain tumor for which there are few effective treatments.
Yale Receives Funding to Study Myasthenia Gravis
The National Institutes of Health through the Rare Diseases Clinical Research Consortia has awarded a research team from Yale University, George Washington University, and Duke University $7.8 million to establish a rare disease network for myasthenia gravis.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
Next frontier in study of gut bacteria: mining microbial molecules
The human gut harbors trillions of invisible microbial inhabitants, referred to as the microbiota, that collectively produce thousands of unique small molecules. The sources and biological functions of the vast majority of these molecules are unknown. Yale researchers recently applied a new technology to uncover microbiota-derived chemicals that affect human physiology, revealing a complex network of interactions with potentially broad-reaching impacts on human health.
Yale Cancer Center Scientists Advise Caution in Immunotherapy Research
In a new study, Yale Cancer Center scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.
Yale scientists study genes misidentified as ‘non-protein coding’
The human genome contains regions that “code” for proteins, which means they have instructions to make protein molecules with specific functions in the body. But Yale researchers have discovered several protein-coding genes that were misidentified as non-protein-coding, and one in particular that plays a key role in the immune system.
Yale Study Shows Immunotherapy Drug Helps Patients with Metastatic Melanoma
When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. A study by Yale Cancer Center researchers published today in the Journal of Clinical Oncology (JCO) shows a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients. The study is one of the first clinical trials aimed at treating the brain metastases with this type of cancer drug.
Hafler Is Elected to the National Academy of Medicine
David A. Hafler, MD, chair of the Department of Neurology, the William S. and Lois Stiles Edgerly Professor of Neurology, and professor of immunobiology, has been elected to the National Academy of Medicine, in recognition of his outstanding achievements in medicine.
New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. However, patients receiving the therapies are older than those in the clinical trials used to evaluate them, pointing to a disconnect between research and practice that should be addressed, they noted.
Lung Cancer Patients Live Longer With Immune Therapy
The odds of survival can greatly improve for people with the most common type of lung cancer if, along with the usual chemotherapy, they are also given a drug that activates the immune system, a major new study has shown.Source: The New York Times
Study: Topical antibiotic triggers unexpected antiviral response
A Yale-led research team made a startling discovery while investigating the effect of bacteria on viral infections. When they applied a common topical antibiotic to mice before or shortly after infection with herpes and other viruses, they found that the antibiotic triggered an antiviral resistance in the animals, the researchers said.
Researchers develop a novel RNA-based therapy to target West Nile Virus
A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.